Skip to main content

Table 4 Relative risks of different safety outcomes and respective 95% CIs calculated using a normal approximation. Data from different studies were pooled when the same outcomes from the same treatments were available and when they referred to doses and/or regimens approved in Brazil

From: The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis – 2019

Outcome Serious adverse effects Discontinuation for any cause
Follow-up time (weeks)
12 to 24
Drug Relative risk 95% CI Relative risk 95% CI
Infliximab [111] 1.30 0.28–6.12 0.78 0.14–4.15
Etanercept [113, 119, 120, 123] 0.84 0.37–1.91 0.81 0.47–1.42
Adalimumab [126, 130, 131] 1.59 0.49–5.06 1.49 0.65–3.39
Golimumab [133, 137, 138] 0.94 0.35–2.56 1.19 0.52–2.75
Certolizumab pegol [139] 1.18 0.43–3.36 0.74 0.34–1.58
Secukinumab [142] 0.81 0.34–1.92 0.55 0.26–1.16